These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1812428)

  • 21. No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.
    Wedege E; Nokleby H; Bjune G
    J Infect Dis; 1999 Jul; 180(1):242; author reply 242-3. PubMed ID: 10353890
    [No Abstract]   [Full Text] [Related]  

  • 22. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the class-1 outer membrane protein from B:15:P1.16 Neisseria meningitidis strains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway.
    Brooks JL; Rosenqvist E; Bjune G; Lambden PR; Heckels JE
    Microb Pathog; 1994 Dec; 17(6):425-30. PubMed ID: 7752883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-meningococcal polysaccharide vaccines].
    Gómez JA; Ferreirós CM; Criado MT
    Enferm Infecc Microbiol Clin; 1997; 15(7):347-8. PubMed ID: 9410045
    [No Abstract]   [Full Text] [Related]  

  • 25. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P; Borrow R
    Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
    Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a meningococcal vaccine.
    Poolman JT
    Infect Agents Dis; 1995 Mar; 4(1):13-28. PubMed ID: 7728353
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of invasive serogroup C meningococcal disease after a community vaccination programme in Rotherham, South Yorkshire.
    Irwin DJ; Kaczmarski EB; Miller JM
    J Public Health Med; 1998 Mar; 20(1):112-4. PubMed ID: 9602462
    [No Abstract]   [Full Text] [Related]  

  • 33. [Interpretation of the laboratory results concerning the protective effect of vaccines].
    Berrón Morato S; Sanz Moreno JC; Martín García E; Salcedo Peláez C; Bermúdez Saugar MP; Vázquez Moreno JA
    Rev Esp Salud Publica; 1998; 72(5):431-3. PubMed ID: 9951337
    [No Abstract]   [Full Text] [Related]  

  • 34. [The serosubtyping of serogroup B meningococci].
    Koroleva IS; Demina AA
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (5):41-4. PubMed ID: 8525731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
    Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
    Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001.
    Tsang RS; Squires SG; Tam TW
    Can J Microbiol; 2003 Oct; 49(10):633-8. PubMed ID: 14663497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006.
    Simões MJ; Cunha M; Almeida F; Furtado C; Brum L
    Epidemiol Infect; 2009 Feb; 137(2):161-5. PubMed ID: 18667108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polysaccharides and membrane vaccines.
    Poolman JT
    Adv Biotechnol Processes; 1990; 13():57-86. PubMed ID: 1970737
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immunity against Neisseria meningitidis in different population groups].
    Pauste Ruiz H; García Imia L; Campa Huergo C; Gutiérrez Hernández M; Valcárcel Novo M
    Rev Cubana Med Trop; 1989; 41(1):135-47. PubMed ID: 2505344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.